Database R R - investigational drugs, therapies and- vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
http://www.cro.quintiles.com/NR/rdonlyres/e25mxrsifbscwcl6uvbfbgvoklxj5buv774lut6tbp2dbrznjxuloeeesrw7wc2bij4nfhyrzevton/QTRN10K2002.pdf page 56
duplicates:http://www.cro.quintiles.com/NR/rdonlyres/eyvqktwcg4mcmhl6bph3ad6qosvvryqsn4e3oojrg5nf6hrba7xqpgrso624hakcfb4krcukksh3cj/QTRN10K2002.pdf http://www.quintiles.com/NR/rdonlyres/e25mxrsifbscwcl6uvbfbgvoklxj5buv774lut6tbp2dbrznjxuloeeesrw7wc2bij4nfhyrzevton/QTRN10K2002.pdf http://www.quintiles.com/NR/rdonlyres/eyvqktwcg4mcmhl6bph3ad6qosvvryqsn4e3oojrg5nf6hrba7xqpgrso624hakcfb4krcukksh3cj/QTRN10K2002.pdf
Hemispherx Biopharma’s Investigational Drug Increases Physical Performance in New Chronic Fatigue Syndrome (CFS) Clinical Study Home - | - Corporate Info - | - R & D - | - Products - | - Investor Relations - | - For the Patient - | - Careers at Hemispherx - - Hemispherx Biopharma Press Release for Monday, April 11, 2005 Hemispherx Biopharma’s Investigational Drug Increases Physical Performance in New Chronic Fatigue Syndrome (CFS) Clinical Study Maximum oxygen consumption increased 10-fold with Ampligen&...
http://www.biopharmafund.nl/Dutch/In_Wall/News/BP_EH_Monthly%20lettersPDF/BioPharmaFund_November_01.pdf New York, December 3, 2001 November letter to the shareholders of BioPharma Fund.
duplicates:http://www.biopharmafund.nl/English/In_Wall/News/BP_EH_Monthly%20lettersPDF/BioPharmaFund_November_01.pdf
http://www.biopharmafund.nl/Dutch/In_Wall/News/BP_EH_Monthly%20lettersPDF/BioPharmaFund_November_01.pdf page 3
duplicates:http://www.biopharmafund.nl/English/In_Wall/News/BP_EH_Monthly%20lettersPDF/BioPharmaFund_November_01.pdf http://www.biopharmafund.nl/Monthly%20lettersPDF/BioPharmaFund_November_01.pdf
http://www.adis.com/files/newsletters/INP/Icov1435.pdf 4 Phenytoin (oral) least costly option for treatment of seizures 5 Heparin: use with caution in renal insufficiency 21 Macrolides do not save your heart 18 OBSTETRICS AND GYNAECOLOGY Metoprolol + amiodarone reduce AF after cardiac surgery 14 Drospirenone/ estradiol for postmenopausal osteoporosis 9 Metoprolol reduces coronary collateral flow during PTCA 19 Estradiol/ drospirenone for...
http://www.adis.com/files/newsletters/INP/Icov1422.pdf 20 CANCER OBSTETRICS AND GYNAECOLOGY Anastrozole of global value in breast cancer
http://www.bioportfolio.com/cgi-bin/acatalog/rbhc0078t.pdf page 4
Quintiles Transnational Corp. and Subsidiaries Securities and Exchange Commission Washington, D
author: Denise M. Wyant
duplicates:http://www.quintiles.com/NR/rdonlyres/ec3mldyzzesbszr3kckjye2sruti3ngflmw45hvorplcj5kskht4v4w4wgvk6ijuzkp74idchzcvdo/Form10QQuarterEndedSeptember302002.pdf
Quintiles Transnational Corp. and Subsidiaries page 6
author: Denise M. Wyant
duplicates:http://www.quintiles.com/NR/rdonlyres/ec3mldyzzesbszr3kckjye2sruti3ngflmw45hvorplcj5kskht4v4w4wgvk6ijuzkp74idchzcvdo/Form10QQuarterEndedSeptember302002.pdf
http://www.cro.quintiles.com/NR/rdonlyres/ep4dckz4j742d3t6wcybxcmeeipu73pfrwysehwxm5plskrzny2y7ll7idrcdnbszqcjrvba3qjzjkd7w3dqrwbxwxa/angusbell24sept.pdf The Success Of Science: The Success Of Science: How To How To Maximise Maximise The Value Of Your Discovery The Value Of Your Discovery Angus Bell Angus Bell Early Development and Laboratory Services Early Development and Laboratory Services 24 September 2002 24 September 2002 Overview Overview Essentials for successful new medicines Essentials for successful new medicines A new...
duplicates:http://www.quintiles.com/NR/rdonlyres/ep4dckz4j742d3t6wcybxcmeeipu73pfrwysehwxm5plskrzny2y7ll7idrcdnbszqcjrvba3qjzjkd7w3dqrwbxwxa/angusbell24sept.pdf
http://www.cro.quintiles.com/NR/rdonlyres/ep4dckz4j742d3t6wcybxcmeeipu73pfrwysehwxm5plskrzny2y7ll7idrcdnbszqcjrvba3qjzjkd7w3dqrwbxwxa/angusbell24sept.pdf page 32
duplicates:http://www.quintiles.com/NR/rdonlyres/ep4dckz4j742d3t6wcybxcmeeipu73pfrwysehwxm5plskrzny2y7ll7idrcdnbszqcjrvba3qjzjkd7w3dqrwbxwxa/angusbell24sept.pdf
Microsoft PowerPoint - Healthcare Venture Capital Healthcare Venture Capital Healthcare Venture Capital "It Ain't a Slam Dunk, Baby" "It Ain't a Slam Dunk, Baby" Samuel D
author: Administrator
Microsoft PowerPoint - Healthcare Venture Capital page 67
author: Administrator
Microsoft PowerPoint - 1191aC [Read-Only] The heart is an 'omnivore' Ad ult Heart Fetal Heart Glucose 30% 85% Lip ids 65% <5% Others 5% 10% Energy Source ...
CVT/Ranolazine Bibliography - RANOLAZINE BIBLIOGRAPHY RANOLAZINE PUBLICATIONS Journal Articles: Letiennne, R., Vie, B., Puech, A., Vieu, S., Le Grand, B., John, G.W. Evidence that ranolazine behaves as a weak b1 and b2 adrenoceptor ...
CVT/Ranolazine - RANOLAZINE Potential new therapeutic approach to angina CVT is developing ranolazine for the potential treatment of chronic angina. Ranolazine represents one of a new class of drugs called partial fatty ...
CVT/Ranolazine Bibliography - RANOLAZINE PUBLICATIONS Journal Articles: Letiennne, R., Vie, B., Puech, A., Vieu, S., Le Grand, B., John, G.W. Evidence that ranolazine behaves as a weak b1 and b2 adrenoceptor antagonist in the rat ...
CVT/Products in Development - PRODUCTS IN DEVELOPMENT CV Therapeutics™ currently has four compounds in clinical trials. Ranolazine , in a new class of compounds known as partial fatty acid oxidation (pFOX) inhibitors, is being ...
CVT/Ranolazine - CVT is developing ranolazine for the potential treatment of chronic angina. Ranolazine represents one of a new class of drugs called partial fatty acid oxidation (pFOX) inhibitors for the potential ...
CVT/Company Information - - CV Therapeutics, Inc. (CVT) headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, ...
CVT/Products in Development - CV Therapeutics™ currently has four compounds in clinical trials. Ranolazine , in a new class of compounds known as partial fatty acid oxidation (pFOX) inhibitors, is being developed for the potential ...
CV Therapeutics, Inc. CV Therapeutics is a biotechnology company developing novel therapeutics for cardiovascular disease with research and development activities in areas which include angina, arrhythmia, congestive heart failure, ...
Microsoft Word - Instability_051302.doc Instability in the Biotech Sector May 13, 2002 New York 740 Broadway; Suite 903 New York, NY 10003 Tel: (212) 477- 9007 Fax: (212) 460- 9028 San Francisco 466 Geary, Suite 550 San Francisco, CA 94102 Tel: (415) 567- 3300 Fax: (415) 567- 3355 ...
author: Lee
http://www.adis.com/files/newsletters/INP/Icov1322.pdf ALLERGY Cetirizine vs petasites in seasonal allergic rhinitis 12 Petasites vs cetirizine in seasonal allergic rhinitis 12 Chronic urticaria and angioedema: treatment reviewed 3 CANCER Aminoglutethimide: adjuvant therapy in breast cancer 17 Antineoplastics for PBSC mobilisation 17 Antineoplastics (high- dose) decrease BMD 20 Antineoplastics: molecular parameters predict survival 12...
